• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
Recently, the latest research results published by the research team of Washington University in St. Louis (WUSTL) in the journal Science Immunology showed that after knockout the important cancer-promoting receptor TREM2 on macrophages, the intestinal microenvironment will also change to an inflammatory state. Among them, Ruminococcus gnavus will proliferate significantly, promoting the proliferation and activation of CD4+T cells in the intestine, and migrating to the tumor site in large numbers, making PD-1 inhibitor treatment more effective.
The MYC gene is a regulatory and proto-oncogene that is overexpressed in most prostate cancers (PCa). A large number of research results have shown that abnormal expression of microRNAs is involved in the occurrence and progression of human prostate cancer. Recently, in a research report entitled "Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the modulation of MYC mRNA via its interaction with BCL-2/Bax, PTEN, and CDK4" published in the international journal Genes & Cancer, scientists from the Pasteur Institute of Iran and other institutions revealed the inhibitory effect of miR-377 on prostate cancer cells through research.
The ecosystem surrounding a tumor, also known as the tumor microenvironment, includes immune cells, tissues, blood vessels, and other cells that interact with each other and with tumor cells. Over time, tumors shape this ecosystem in their own interests, monopolizing all nutrients and protecting them from the host's immune attack. In order to better understand the role of the ecosystem in cancer risk, occurrence, and treatment.
Recently, researchers from Yale University and other institutions published a research paper titled "In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy" in the journal Nature Biotechnology. After years of technical research, the research team used the AAV-transposon system to integrate the CRISPR library into the genome, overcoming the obstacles of low efficiency of primary NK cell transduction and gene editing. Through four parallel CRISPR screening experiments and single-cell sequencing data, the study discovered a new target, CALHM2, which provides a new therapeutic target for NK cell tumor immunity.
In a new study, researchers from the University of California, Los Angeles discovered that a protein called MYCT1 plays a key role in regulating the self-renewal of human hematopoietic stem cells (HSCs) by helping them sense and interpret signals from their environment. This discovery brings scientists one step closer to developing a method to expand hematopoietic stem cells in laboratory dishes. This will make life-saving hematopoietic stem cell transplants more accessible and improve the safety of hematopoietic stem cell-based therapies, such as gene therapy. The relevant research results were recently published in the journal Nature, with the title of the paper "MYCT1 controls environmental sensing in human haematopoietic stem cells".
In recent years, the potential of RNA vaccines in cancer treatment has attracted widespread attention. With the successful launch of the COVID-19 vaccine, RNA technology has demonstrated its potential for rapid development and customization, bringing new hope to cancer treatment. Recently, Nature's report "How personalized cancer vaccines could keep tumours from coming back" explored the application of RNA vaccines in personalized cancer treatment, especially its prospects in the treatment of melanoma.
Recently, the Jeremy M. Sullivan/Charlotte J. Sumner team at Johns Hopkins University published a study. They found that mutations in the transient receptor potential vanilloid receptor 4 (Trpv4) gene in neurovascular endothelial cells can destroy the integrity of the blood-spinal cord barrier and drive the degeneration of motor neurons in a non-cell autonomous manner. Administration of TRPV4-specific antagonists can restore the integrity of the blood-spinal cord barrier and improve the motor neuron degeneration phenotype of Trpv4 mutant mice. The relevant research was published in Science Translational Medicine.
RNA interference (RNAi) technology has shown great potential in the treatment of genetic diseases and viral infections. It is also considered an attractive therapeutic approach to achieve functional cure of hepatitis B by inducing antigen suppression, reducing viremia, and silencing covalently closed circular DNA (cccDNA). siRNA-based therapies can also alleviate immune tolerance induced by high viral antigens, providing opportunities for subsequent immune stimulation to gain immune control of the virus.
Researchers from the University of Zurich published a review article in the journal Cell titled: Past, present, and future of CRISPR genome editing technologies. Genome editing has become a transformative force in life sciences and human medicine, providing unprecedented opportunities to dissect complex biological processes and fundamentally treat genetic diseases. CRISPR-based technologies, with their remarkable efficiency and ease of programmability, are at the forefront of this revolution. In this review, the authors discuss the current state of CRISPR gene editing technologies in research and therapy, highlighting the limitations that restrict them and the technological innovations developed in recent years to address these issues. In addition, the current applications of gene editing in human health and therapy are examined and summarized. Finally, potential developments that may affect gene editing technologies and their applications in the future are outlined.
In a new study, researchers from the Ludwig Cancer Research Center have developed a new type of immunotherapy that uses a two-pronged approach to attack solid tumors to enhance the immune system's ability to target and eliminate cancer cells. The relevant research results were published in the Journal of Clinical Investigation. The paper is titled "Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells."
